Melanotan-2 (MT-2) is a synthetic derivative of human alpha-melanocyte-stimulating hormone (α-MSH), developed at the University of Arizona in the 1980s. The initial purpose was to create a sunless tanning alternative, inspired by α-MSH’s ability to induce sexual arousal and skin darkening in rodents. However, as research progressed, MT-2’s diverse effects were unveiled. These include enhancing sexual arousal, promoting skin pigmentation, reducing compulsive behavior, managing addiction, suppressing hunger, decreasing glucagon production, and even potentially reversing certain features associated with autism. Melanotan-2 research has shown it to enhance sexual arousal, promote skin pigmentation through melanocyte activation and reduce compulsive/addictive behaviors.

PT-141, also called Bremelanotide (generic clinical name), is a heavily modified synthetic derivative of alpha-melanocyte-stimulating hormone. It has been tested in clinical trials as a treatment for both male/female hypoactive sexual desire disorder and acute hemorrhage. PT-141 is an agonist for the melanocortin-4 and melanocortin-1 receptors. Research shows that it promotes sexual arousal and stimulates the immune system.